Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 44,420 | 25,397 | 28,497 | 13,986 | 21,131 |
| TOTAL | $49,051 | $29,447 | $31,973 | $16,327 | $24,035 |
| Non-Current Assets | |||||
| Intangibles | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 |
| Other Non-Current Assets | 590 | 944 | 1,069 | 1,191 | 556 |
| TOTAL | $2,504 | $2,858 | $2,983 | $3,105 | $2,470 |
| Total Assets | $51,555 | $32,305 | $34,956 | $19,432 | $26,505 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,305 | 3,336 | 3,756 | 3,500 | 4,547 |
| Accrued Expenses | 3,021 | 2,083 | 2,571 | 5,466 | 5,490 |
| TOTAL | $5,925 | $5,999 | $6,888 | $9,510 | $10,613 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 157 | 309 | 457 | 0 |
| TOTAL | $N/A | $157 | $309 | $457 | $N/A |
| Total Liabilities | $5,925 | $6,156 | $7,197 | $9,967 | $10,613 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 142,442 | 105,298 | 99,777 | 90,847 | 70,382 |
| Common Shares | 12 | 10 | 9 | 7 | 6 |
| Retained earnings | -267,330 | -260,539 | -253,938 | -248,125 | -241,388 |
| TOTAL | $45,630 | $26,149 | $27,759 | $9,465 | $15,892 |
| Total Liabilities And Equity | $51,555 | $32,305 | $34,956 | $19,432 | $26,505 |